SCHEMBL1505146

SCHEMBL1505146

COC(=O)c1cc(Cl)ccc1OCCSC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 1/20 0.49
MAPT P10636 3/20 0.47
ABL1 P00519 1/20 0.47
HTR2C P28335 2/20 0.45
LMNA P02545 1/20 0.45
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HSP90AA1 P07900 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421995 0.84 SLC6A4 (0.51) S1PR4MAPTABL1LMNAMEN1
SCHEMBL929622 0.84 MAPT (0.50) S1PR4MAPTABL1LMNAMEN1
SCHEMBL4360418 0.84 LMNA (0.51) S1PR4MAPTABL1LMNAMEN1
SCHEMBL1505120 0.84 S1PR4 (0.52) S1PR4MAPTABL1LMNAMEN1
SCHEMBL1154092 0.83 KDM4E (0.54) S1PR4MAPTABL1LMNAMEN1
SCHEMBL2796366 0.83 MAPT (0.52) S1PR4MAPTABL1LMNAHSP90AA1
Hydrochloric Acid SCHEMBL1505031 0.82 ABL1 (0.51) S1PR4MAPTABL1LMNAMEN1
SCHEMBL2799514 0.82 MAPT (0.55) S1PR4MAPTABL1LMNAMEN1
SCHEMBL17040919 0.81 SMN1; SMN2 (0.58) MAPTABL1LMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL1505095 0.81 MAPT (0.50) S1PR4MAPTABL1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011027156-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 WO disclosed
WO-2011027156-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 WO disclosed
US-20110059043-A1 CHEMICAL COMPOUNDS ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 US disclosed
US-20110059043-A1 CHEMICAL COMPOUNDS ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 US disclosed
US-20110059043-A1 CHEMICAL COMPOUNDS ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059043-A1 CHEMICAL COMPOUNDS CYP2E1, CNR1, CYP3A5 S1PR4 2819/4885MAPT 2272/4885ABL1 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.